Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verinurad and Allopurinol Safety/PK in Healthy Asian and Chinese Subjects
NCT03836599Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of verinurad in chronic kidney disease (CKD) and hyperuricemia (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events, Number of participants with abnormal findings in electrocardiography and 4 more. Started Jan 2019; status: completed.
02
Drugs
verinurad
03
Conditions
chronic kidney disease (CKD)hyperuricemia
Beyond the preview
Go deeper on NCT03836599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836599.